Agios Pharm

NASDAQ AGIO

Data sourced from

and

Download Data

Agios Pharm Liabilities to Equity Ratio 2 year CAGR for the year ending December 31, 2023: 17.39%

Agios Pharm Liabilities to Equity Ratio 2 year CAGR is 17.39% for the year ending December 31, 2023, a 126.05% change year over year. The liabilities to equity ratio, also known as the leverage ratio, measures the proportion of a company's total liabilities to its shareholders' equity. It is calculated by dividing the total liabilities by the shareholders' equity. This ratio provides insights into the extent to which a company relies on debt financing compared to equity financing. A higher ratio indicates higher financial leverage, which can amplify both returns and risks for the company's shareholders. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Agios Pharm Liabilities to Equity Ratio for the year ending December 31, 2022 was 0.13, a 11.04% change year over year.
Agios Pharm Liabilities to Equity Ratio for the year ending December 31, 2021 was 0.11, a -90.06% change year over year.
Agios Pharm Liabilities to Equity Ratio for the year ending December 31, 2020 was 1.14, a 190.56% change year over year.
Agios Pharm Liabilities to Equity Ratio for the year ending December 31, 2019 was 0.39, a 57.14% change year over year.

NASDAQ: AGIO

Agios Pharm

CEO	Dr. Bruce D. Car DACVP, Ph.D.
IPO Date	July 24, 2013
Location	United States
Headquarters	88 Sidney Street, Cambridge, MA, United States, 02139-4169
Employees	383
Sector	Healthcare
Industry	Biotechnology

Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Key trends